Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14295558 | 0.86 | ALDH1A1 (0.53) | ALDH1A1RECQLSMN1; SMN2MEN1KMT2A | |
| SCHEMBL11763698 | 0.80 | MEN1 (0.68) | ALDH1A1RECQLSMN1; SMN2MEN1KMT2A | |
| SCHEMBL13145684 | 0.78 | ALDH1A1 (0.51) | ALDH1A1RECQLSMN1; SMN2MAPK14POLB | |
| SCHEMBL14401688 | 0.78 | ALDH1A1 (0.60) | ALDH1A1RECQLSMN1; SMN2MEN1KMT2A | |
| SCHEMBL23022431 | 0.77 | GPR35 (0.46) | ALDH1A1SMN1; SMN2MEN1KMT2AMAPK1 | |
| SCHEMBL22928093 | 0.77 | CA2 (0.41) | ALDH1A1RECQLSMN1; SMN2MEN1KMT2A | |
| SCHEMBL24252064 | 0.73 | CTSS (0.47) | ALDH1A1MAPK14POLBPDK2 | |
| SCHEMBL3105855 | 0.73 | CA2 (0.44) | ALDH1A1MEN1KMT2AMAPK1MAPK14 | |
| SCHEMBL14003501 | 0.72 | ALDH1A1 (1.00) | ALDH1A1RECQLSMN1; SMN2MEN1KMT2A | |
| SCHEMBL8830517 | 0.72 | SMN1; SMN2 (0.73) | ALDH1A1RECQLSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | ALDH1A1 1572/4885RECQL 4832/4885SMN1; SMN2 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.